세계의 신경섬유종증 치료 시장 보고서(2025년)

Neurofibromatosis treatment involves addressing a genetic disorder that causes tumors to develop on nerve tissue, which can occur anywhere in the body, including the brain, spinal cord, and peripheral nerves. The treatment aims to manage symptoms, slow disease progression, and prevent complications associated with the condition.

Neurofibromatosis treatment encompasses approaches tailored for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Neurofibromatosis type 1 (NF1) is a hereditary disorder characterized by the development of tumors on nerves throughout the body. Various treatment modalities such as medications, surgical interventions, radiation therapy, and other specialized approaches are utilized by a range of end-users, including hospitals, clinics, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The neurofibromatosis treatment market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis treatment market statistics, including neurofibromatosis treatment industry global market size, regional shares, competitors with a neurofibromatosis treatment market share, detailed neurofibromatosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurofibromatosis treatment industry. This neurofibromatosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $13.09 billion in 2024 to $14.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to aging population, advancements in ophthalmology, patient-centered care, global healthcare access.

The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $24.25 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include vision rehabilitation services, collaborative care models, data analytics and ai, optic nerve prostheses and implants.

The forecast of 13.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. rare disease care by increasing costs for Mitogen-activated protein kinase kinase(MEK) inhibitor therapies and tumor suppressor gene medications imported from Switzerland and the UK, potentially compromising tumor management and raising specialty pharmacy costs for Neurofibromatosis(NF) patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing healthcare expenditure is expected to drive the expansion of the neurofibromatosis treatment market. Healthcare expenditure includes all costs related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. It plays a vital role in advancing neurofibromatosis treatment, which involves various medical procedures such as surgeries, biopsies, and imaging tests like MRI and CT scans. Additionally, healthcare spending supports services like general medical care and neurofibromatosis treatment. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, compared to a modest 0.9% growth in 2022. Thus, the rise in healthcare expenditure is fueling the growth of the neurofibromatosis treatment market.

The growing focus on research and development (R&D) is expected to accelerate the growth of the neurofibromatosis treatment market. R&D activities refer to the increasing efforts by organizations to invest in systematic studies and innovative projects aimed at creating new products, technologies, or processes. The surge in R&D activities is driven by the need for innovation to maintain competitive edge, address consumer demands, and adapt to technological changes. The emphasis on developing treatments for neurofibromatosis has led to a rise in R&D efforts, with companies focusing on understanding the disease's underlying mechanisms and exploring new treatment options. For instance, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade group representing the pharmaceutical industry, reported that pharmaceutical R&D expenditure in Europe reached $49.5 billion (€44.5 billion) in 2022, marking a 6.45% increase from $46.5 billion (€42.5 billion) in 2021. Therefore, the growing emphasis on R&D is driving the expansion of the neurofibromatosis treatment market.

Leading companies in the neurofibromatosis treatment market are advancing the development of innovative drugs and investigational targeted therapies, such as MEK inhibitors, to maintain their competitive edge. MEK inhibitors are a class of targeted therapies that block the MEK enzyme, which is part of the MAPK signaling pathway. This inhibition helps treat cancers and genetic disorders like neurofibromatosis by preventing cell growth and tumor progression. For example, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, completed its submission of a new drug application (NDA) to the FDA for Mirdametinib, a treatment aimed at both children and adults with NF1-PN. Mirdametinib is a selective MEK inhibitor designed to target specific pathways responsible for the growth of neurofibromas. The FDA will review the safety and efficacy of this treatment, which could significantly improve the outcomes for individuals suffering from NF1-PN.

In October 2022, Pasithea Therapeutics, a prominent biotechnology company based in the US, completed the acquisition of AlloMek Therapeutics for $1.05 million. This strategic move is set to significantly enhance Pasithea Therapeutics' drug development efforts, with a specific focus on the Central Nervous System (CNS). AlloMek Therapeutics, a pharmaceutical company also based in the US, specializes in the development of treatments for a range of conditions including neurofibromatosis, congenital muscular disease, and catastrophic cardiomyopathy.

Major companies operating in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Vertex Pharmaceuticals Inc., Dr. Reddy's Laboratories, BioMarin Pharmaceutical, Allergan, BeiGene Ltd., BioXcel Therapeutics Inc., Blueprint Medicines Corp., Genway BioTech, SpringWorks Therapeutics, LGM Pharma LLC, Biotechnica Pharma Global, Affymax Inc.

North America was the largest region in the neurofibromatosis treatment market in 2024. The regions covered in neurofibromatosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurofibromatosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurofibromatosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurofibromatosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurofibromatosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Neurofibromatosis 1 (NF1); Neurofibromatosis 2 (NF2); Schwannomatosis
• 2) By Treatment: Medications; Surgery; Radiation Therapy; Other Treatments
• 3) By End-Users: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Neurofibromatosis 1 (NF1): Surgical Interventions; Medication for Symptom Management; Genetic Counseling
• 2) By Neurofibromatosis 2 (NF2): Surgical Interventions; Radiation Therapy; Medication for Symptom Management
• 3) By Schwannomatosis: Surgical Interventions; Pain Management Therapies; Genetic Counseling
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GSK PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Vertex Pharmaceuticals Inc.; Dr. Reddy's Laboratories; BioMarin Pharmaceutical; Allergan; BeiGene Ltd.; BioXcel Therapeutics Inc.; Blueprint Medicines Corp.; Genway BioTech; SpringWorks Therapeutics; LGM Pharma LLC; Biotechnica Pharma Global; Affymax Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurofibromatosis Treatment Market Characteristics

3. Neurofibromatosis Treatment Market Trends And Strategies

4. Neurofibromatosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neurofibromatosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurofibromatosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurofibromatosis Treatment Market Growth Rate Analysis
• 5.4. Global Neurofibromatosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurofibromatosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurofibromatosis Treatment Total Addressable Market (TAM)

6. Neurofibromatosis Treatment Market Segmentation

• 6.1. Global Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurofibromatosis 1 (NF1)
• Neurofibromatosis 2 (NF2)
• Schwannomatosis
• 6.2. Global Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgery
• Radiation Therapy
• Other Treatments
• 6.3. Global Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 1 (NF1), By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions
• Medication for Symptom Management
• Genetic Counseling
• 6.5. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Neurofibromatosis 2 (NF2), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions
• Radiation Therapy
• Medication for Symptom Management
• 6.6. Global Neurofibromatosis Treatment Market, Sub-Segmentation Of Schwannomatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions
• Pain Management Therapies
• Genetic Counseling

7. Neurofibromatosis Treatment Market Regional And Country Analysis

• 7.1. Global Neurofibromatosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurofibromatosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurofibromatosis Treatment Market

• 8.1. Asia-Pacific Neurofibromatosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurofibromatosis Treatment Market

• 9.1. China Neurofibromatosis Treatment Market Overview
• 9.2. China Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurofibromatosis Treatment Market

• 10.1. India Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurofibromatosis Treatment Market

• 11.1. Japan Neurofibromatosis Treatment Market Overview
• 11.2. Japan Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurofibromatosis Treatment Market

• 12.1. Australia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurofibromatosis Treatment Market

• 13.1. Indonesia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurofibromatosis Treatment Market

• 14.1. South Korea Neurofibromatosis Treatment Market Overview
• 14.2. South Korea Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurofibromatosis Treatment Market

• 15.1. Western Europe Neurofibromatosis Treatment Market Overview
• 15.2. Western Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurofibromatosis Treatment Market

• 16.1. UK Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurofibromatosis Treatment Market

• 17.1. Germany Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurofibromatosis Treatment Market

• 18.1. France Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurofibromatosis Treatment Market

• 19.1. Italy Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurofibromatosis Treatment Market

• 20.1. Spain Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurofibromatosis Treatment Market

• 21.1. Eastern Europe Neurofibromatosis Treatment Market Overview
• 21.2. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurofibromatosis Treatment Market

• 22.1. Russia Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurofibromatosis Treatment Market

• 23.1. North America Neurofibromatosis Treatment Market Overview
• 23.2. North America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurofibromatosis Treatment Market

• 24.1. USA Neurofibromatosis Treatment Market Overview
• 24.2. USA Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurofibromatosis Treatment Market

• 25.1. Canada Neurofibromatosis Treatment Market Overview
• 25.2. Canada Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurofibromatosis Treatment Market

• 26.1. South America Neurofibromatosis Treatment Market Overview
• 26.2. South America Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurofibromatosis Treatment Market

• 27.1. Brazil Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurofibromatosis Treatment Market

• 28.1. Middle East Neurofibromatosis Treatment Market Overview
• 28.2. Middle East Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurofibromatosis Treatment Market

• 29.1. Africa Neurofibromatosis Treatment Market Overview
• 29.2. Africa Neurofibromatosis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurofibromatosis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurofibromatosis Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurofibromatosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Neurofibromatosis Treatment Market Competitive Landscape
• 30.2. Neurofibromatosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Neurofibromatosis Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. GSK PLC
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Vertex Pharmaceuticals Inc.
• 31.10. Dr. Reddy's Laboratories
• 31.11. BioMarin Pharmaceutical
• 31.12. Allergan
• 31.13. BeiGene Ltd.
• 31.14. BioXcel Therapeutics Inc.
• 31.15. Blueprint Medicines Corp.

32. Global Neurofibromatosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurofibromatosis Treatment Market

34. Recent Developments In The Neurofibromatosis Treatment Market

35. Neurofibromatosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Neurofibromatosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurofibromatosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurofibromatosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer